Kabra Drugs Ltd

Kabra Drugs Ltd

Kabra Drugs Ltd has submitted the voting results of its 37th Annual General Meeting, held on September 30, 2026, as per SEBI regulations.

Kabra Drugs Ltd

Kabra Drugs Ltd (formerly known as Aanjaay Industries Ltd) held its 37th Annual General Meeting on September 30, 2026, where the company adopted audited financial statements and re-appointed Mr. Kuniamuthur Nanjappan Anand as a director. The company also appointed Ms. Moonam Kapoor and Mrs. Twinkle Agarwal as additional non-executive independent directors and company secretary, respectively. The voting results will be announced within 48 hours and posted on the company's website.

Kabra Drugs Ltd

Kabra Drugs Ltd has announced the closure of its trading window for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026.

Kabra Drugs Ltd

Kabra Drugs Ltd, now known as Aanjaay Industries Ltd, has submitted its annual report for the financial year 2025-2026, along with a notice for its 37th Annual General Meeting on September 30, 2026. The report includes changes in the board of directors and key managerial personnel, as well as the appointment of a new non-executive independent director and secretarial auditor.

Kabra Drugs Ltd

Kabra Drugs Ltd has announced book closure and e-voting schedule for its upcoming Annual General Meeting (AGM) to be held on September 30, 2026.

Kabra Drugs Ltd

Kabra Drugs Ltd has appointed M/s Karthik L & Associates as its Internal Auditor for the Financial Year 2026-2027, in compliance with the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.

Kabra Drugs Ltd

Kabra Drugs Ltd has appointed Mrs. Twinkle Agarwal as its Secretarial Auditor for the financial year 2026–2027 to 2027–2031, in compliance with the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.

Kabra Drugs Ltd

The Board of Directors of Kabra Drugs Ltd held a meeting on September 2, 2026, and considered and approved various items, including the Director's Report and Corporate Governance Report for the financial year ended March 31, 2026. The company also announced the re-appointment of Mr. Kuniamuthur Nanjappan Anand as Director, the appointment of M/s Karthik L & Associates as Internal Auditors, and the appointment of Ms. Moonam Kapoor and Mrs. Twinkle Agarwal as Directors and Secretarial Auditor, respectively. The meeting also approved the Notice of the 37th Annual General Meeting, which will be held on September 30, 2026.

Kabra Drugs Ltd

Kabra Drugs Ltd has changed its registered office address from Indore to Chennai, as per the order of the Regional Director and Registrar of Companies. The change is effective from August 28, 2026.

Kabra Drugs Ltd

Kabra Drugs Ltd has informed BSE that a meeting of the Board of Directors is scheduled on 02/09/2026 to consider and approve various business, including Director's Report, closure of Register of Members, and appointment of Directors and Auditors.

Kabra Drugs Ltd

Kabra Drugs Ltd has reconstituted its Board of Directors and Committees as per Regulation 30 of SEBI (LODR) Regulations, 2015, effective from August 12, 2026. The new composition includes Nanjappan Aravind as Executive Director, Managing Director, and Chairperson, and four independent directors: Nikita Sinha, Ritu Tiwari, Moonam Kapoor, and Kuniamuthur Nanjappan Anand.

Kabra Drugs Ltd

Kabra Drugs Ltd has published an unaudited financial results for the quarter ended on 30th June 2026 in a newspaper advertisement.

Kabra Drugs Ltd

Kabra Drugs Ltd announced the resignation of Ms. Anand Anitha as Director of the Company, effective August 12, 2026, citing personal reasons.

Kabra Drugs Ltd

Kabra Drugs Ltd, now known as Aanjaay Industries Ltd, has submitted an undertaking to the BSE stating that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company for the quarter ended 30th June 2026. The company has not issued any shares through public issue, rights issue, or preferential issue during this period.

Kabra Drugs Ltd

Kabra Drugs Ltd (formerly known as Kabra Drugs Limited) has announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a net profit of ₹212.30 lakhs, with revenue from operations at ₹4621.68 lakhs and total income at ₹4629.33 lakhs.

Kabra Drugs Ltd

Kabra Drugs Ltd (formerly known as Kabra Drugs Limited) has announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a net profit of ₹212.30 lakhs, with earnings per share (EPS) of ₹0.90. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 12th, 2026.

Kabra Drugs Ltd

Kabra Drugs Ltd has scheduled a Board Meeting on 12-Aug-2026 to consider unaudited financial results for Q2 FY2026-27, resignation of a director, and other business.